Sofinnova Partners Closed €82 Million Medtech Fund
The firm will utilize this capital to launch new medical technology companies across Europe and the United States.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you believe private venture capital investment effectively accelerates the development of helpful new medical technology?
Sofinnova Partners has closed its oversubscribed MD Start IV fund at €82 million to support its medtech company-creation strategy. This latest vehicle surpasses the €63 million raised for the firm's predecessor fund.
Why it matters
The successful capital raise signals continued investor appetite for hands-on, early-stage medical technology ventures despite broader economic headwinds. It provides Sofinnova with the dry powder to continue its strategy of building companies from the ground up rather than purely investing in existing ones.
The firm closed the oversubscribed fund at €82 million, a notable increase over the €63 million raised for the previous iteration. Sofinnova Partners manages over €4 billion in total assets and has backed 500 companies since its founding in 1972.
The players
Sofinnova Partners
A Paris-headquartered venture capital firm managing over €4 billion in assets and specializing in the life sciences sector.
Anne Osdoit
A partner at Sofinnova Partners who oversees the firm's medtech company-creation strategy.
Cecile Dupont
A partner at Sofinnova Partners responsible for executing the firm's early-stage investment and operational strategies.
Mano Iyer
A partner at Sofinnova Partners focused on medtech venture development and operational support for founders.
The details
The MD Start IV fund focuses on a company-creation strategy that embeds firm partners directly into the operations of early-stage medtech startups. Partners Anne Osdoit, Cecile Dupont, and Mano Iyer will lead this operational approach, providing both capital and hands-on guidance to founders. This strategy aims to accelerate development cycles and secure subsequent financing, similar to outcomes seen in previous portfolio companies like BrightHeart and CorWave.
Timeline
Sofinnova Partners was founded in 1972.
The firm announced the final closing of the fund on September 28, 2026.
The firm plans to launch six to eight new medtech companies over the next five years.
Market Landscape
The success of the MD Start IV fund follows the operational pattern established by the Sofinnova MD Start III fund. This expansion validates the firm's strategy of increasing its capital base as its portfolio companies achieve significant milestones, such as successful clinical adoption and follow-on financing.
Operators in the medtech space should monitor this deployment as a signal for potential early-stage partnership and co-development opportunities over the next five years. Business owners should watch how the firm’s hands-on model affects the valuation and scaling speed of their own competitors.
The takeaway
The move underscores that specialized, operational-heavy venture models remain a primary engine for scaling complex medical hardware. Owners should track the firm's planned launch of six to eight new companies as a bellwether for innovation shifts in the global medtech sector.
Further reading
For more on the current state of life sciences investment, see the latest updates in Healthcare.
Live Poll
Do you believe private venture capital investment effectively accelerates the development of helpful new medical technology?
